Eye-dea to Impact
A modern blueprint for investigator-initiated trials
Shorten your path from concept to IRB approval, clean data, and a publishable paper—without burning nights and weekends.
10+ years in ophthalmic trials
50+ peer-reviewed publications
Dozens of IITs supported
Supporting eye care professionals on studies funded by leading ophthalmic companies—including Alcon, Johnson & Johnson, and Topcon.
10+ years in ophthalmic trials
50+ peer-reviewed publications
Dozens of IITs supported
Supporting eye care professionals on studies funded by leading ophthalmic companies—including Alcon, Johnson & Johnson, and Topcon.
Who this book is for
Eye care leaders and emerging clinicians who want to simplify IITs, achieve results
without academic red tape, and build confidence in research publishing.
Ophthalmologists and optometrists planning or running an IIT
Private practices and ASCs that want results without an academic admin team
Early-career clinicians who need a clear, repeatable process
What you’ll be able to do (outcomes)
By the end of this book, you’ll have the tools to turn ideas into fundable, IRB-ready synopses in record time—without the missteps that waste budgets and stall trials. You’ll know exactly how to produce results that reviewers respect, journals accept, and your peers notice.
Turn an idea into a fundable, IRB-ready synopsis in days—not months
Avoid common design errors that sink timelines and budgets
Recruit efficiently and keep follow-up rates high
Collect analyzable data (not just “filled forms”)
Write results that reviewers take seriously—and get them published
Introducing the LENS System
We support investigator-initiated trials through a proven four-phase system designed specifically for eye-care professionals.
Launch with Focus
IRB-ready documents and approvals—fast.
Enroll with Confidence
Recruit fast, retain reliably—with workflows designed for busy eye-care clinics.
Notice the Insights
Compliant data capture and expert statistical analysis.
Share the Results
Get published in medical journals and recognized at top conferences.
Ready to lead your own investigator-initiated trial with confidence?
Pre-order now and be first to gain access to this comprehensive, practical guide to clinical research success.
What’s Inside
A condensed look at the structure and topics covered in the upcoming guide — built to move you from idea to publication with clarity and confidence.
Part I — Building a Strong Foundation
Learn what it really takes to run a successful Investigator-Initiated Trial (IIT).
You’ll start by understanding the clinical research landscape, assessing your readiness, and avoiding the common pitfalls that derail many studies. See how well-run IITs not only advance patient care but also elevate your professional reputation and practice growth.
Part II — Mastering the Methods Behind Impactful Trials
Move from concept to completion with clarity.
Discover step-by-step guidance on designing a high-quality study, navigating ethics approval, recruiting and retaining participants, and managing data that leads to meaningful results. Learn practical frameworks to publish with confidence — from writing abstracts to surviving peer review.
Part III — Implementation
See how real-world investigators apply these methods to retrospective, prospective, and hybrid trials.
Explore emerging trends — from AI and adaptive trial design to decentralized research models — and uncover new opportunities for collaboration and funding. End with proven tools and resources to accelerate your own research journey.
Why listen to me
I’m Brad Hall, founder of Sengi Clinical. I help eye-care clinicians turn great ideas into successful investigator-initiated trials (IITs)—from planning and execution to analysis and publication. With 10+ years in ophthalmic research, 50+ peer-reviewed publications, and a proven track record supporting IITs in glaucoma, cataract/refractive, and cornea, I know how to simplify the process and deliver results that make an impact.
Get ready—Eye-dea to Impact is coming soon!
Pre-order now to gain early access to the blueprint for successful investigator-initiated trials.
